Streetbeat News

Revenues

VYGR

Voyager Therapeutics (NASDAQ:VYGR) reported Q2 2024 GAAP EPS of $(0.18), beating the $(0.43) estimate. Sales were $29.578M, surpassing the $9.461M estimate and showing a 509.48% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:10 pm

UPST

Upstart has provided its financial outlook for Q3 2024, expecting revenue of approximately $150 million, which is higher than the estimated $124.5 million. The company also anticipates a net loss of approximately $49 million and an adjusted net loss of approximately $14 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:10 pm

PGNY

Progyny has released its financial projections for FY 2024 and Q3 2024. For FY 2024, the company expects revenue between $1.165 billion and $1.20 billion, net income between $55.4 million and $62.4 million, and adjusted EPS between $1.53 and $1.61. For Q3 2024, revenue is projected between $290 million and $303 million, net income between $10.7 million and $13.2 million, and adjusted EPS between $0.35 and $0.38.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:10 pm

AGL

Agilon Health (NYSE:AGL) reported Q2 sales of $1.483 billion, missing the analyst consensus estimate of $1.560 billion by 4.91%. Despite the miss, sales increased by 29.07% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:09 pm

UPST

Upstart Holdings (NASDAQ: UPST) reported Q2 2024 adjusted EPS of $(0.17), beating the analyst estimate of $(0.39). Sales were $128.00M, also surpassing the $124.54M estimate. However, sales decreased by 5.72% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:08 pm

MOS

Mosaic (NYSE:MOS) reported Q2 earnings of $0.54 per share, missing the analyst estimate of $0.66 by 18.18%. Sales were $2.80 billion, also missing the estimate of $2.93 billion by 4.57%. Both earnings and sales showed significant declines compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:08 pm

TREX

Trex Co (NYSE:TREX) reported Q2 2024 earnings per share (EPS) of $0.80, beating the analyst consensus estimate of $0.78. However, the company's sales of $376.470 million missed the estimate of $387.863 million. Despite the miss, sales increased by 5.59% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:07 pm

INSP

Inspire has increased its 2024 revenue guidance to $788M-$798M, representing a 26%-28% growth. The company maintains its gross margin guidance of 83%-85% and raises its 2024 diluted net income per share guidance to $0.60-$0.80. Additionally, Inspire plans to open 52-56 new U.S. medical centers and 12-14 new U.S. territories per quarter.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:06 pm

EXEL

Exelixis (NASDAQ:EXEL) reported Q2 2024 adjusted EPS of $0.84, significantly beating the estimate of $0.30. The company also reported sales of $637.178 million, surpassing the estimate of $465.005 million and marking a 35.61% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:06 pm

DVA

DaVita (NYSE:DVA) reported Q2 earnings of $2.59 per share, beating the analyst estimate of $2.54. Sales were $3.19 billion, surpassing the $3.15 billion estimate. This represents a 24.52% increase in earnings and a 6.22% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:06 pm